Informed Prostate Cancer Patient Support

New Guidelines: Start PSA Screening Earlier in Black Men medscape.com Sharon Worcester, MA Lowering the recommended age for baseline prostate-specific antigen (PSA) would reduce prostate cancer deaths by about 30% in Black men without significantly increasing the rate of overdiagnosis, according to new screening guidelines from the Prostate Cancer Foundation. Specifically, baseline PSA testing in Black men should begin at age 40-45, sooner than current guidelines recommend, and should be followed by regular screening intervals, preferably annually, at least until age 70, a multidisciplinary panel of experts and patient advocates determined based on a comprehensive literature review. The panel's findings were presented in a poster at the 2024 American Society of Clinical Oncology Genitourinary Symposium . "Black men in the United States are consid

Synthetic Histology Images for Training AI Models: A Novel Approach to Improve Prostate Cancer Diagnosis | bioRxiv biorxiv.org Synthetic Histology Images for Training AI Models: A Novel Approach to Improve Prostate Cancer Diagnosis Derek J Van Booven 3–4 minutes New Results Follow this preprint , Cheng-Bang Chen , Oleksander Kryvenko , Sanoj Punnen , Victor Sandoval , Sheetal Malpani , Ahmed Noman , Farhan Ismael , Andres Briseño , Yujie Wang , Himanshu Arora 0 1 0 0 5 0 TRiP Peer Reviews 0 Community Reviews 1 Automated Services 0 Blog/Media Links 0 Videos 5 Tweets ABSTRACT Prostate cancer (PCa) poses significant challenges for timely diagnosis and prognosis, leading to high mortality rates and increased disease risk and treatment costs. Recent advancements in machine

More Side Effects With Local Therapies for Prostate Cancer medscape.com Nadine Eckert Men with advanced prostate cancer undergoing local therapies such as radiation therapy or radical prostatectomy experience significantly more gastrointestinal and sexual issues, along with problems with incontinence, in the following years, than systemically treated patients. These were the findings of a retrospective cohort study in JAMA Network Open. The standard treatment of advanced prostate cancer is androgen deprivation therapy (ADT). "The role of local therapy has been debated for several years. Studies have shown that radiation therapy or radical prostatectomy can improve patient survival under certain conditions," said Hubert Kübler, MD, director of the Clinic and Polyclinic for Urology and Pediatric Urology at the University Hospital Würzburg in Ge

Getting fitter can reduce prostate cancer risk by 35%, study finds | Prostate cancer | The Guardian theguardian.com Andrew Gregory Men can reduce their risk of prostate cancer by as much as 35% by doing a little more jogging, cycling or swimming, a study suggests. Boosting cardiorespiratory fitness by only 3% over the course of a year was linked to a much lower chance of developing the disease. The findings prompted the researchers to encourage men to boost their fitness levels to help cut their prostate cancer risk. “The more intensive activity, the lower the requirement for duration and frequency,” said the study’s co-author Dr Kate Bolam, of the Swedish School of Sport and Health Sciences in Stockholm. “Also, getting more muscles involved will have greater aerobic challenge on the cardiovascular system. “Hence, activities that involve the lower body … b

The US will see record-breaking number of new cancer cases in 2024 - Futurity

Can HPV cause prostate cancer? Research and more medicalnewstoday.com In males, human papillomavirus (HPV) can cause genital warts on the penis and elsewhere around the genital and anal area. The warts may appear as small or large bumps, which may be flat, raised, or cauliflower-shaped. Human papillomavirus (HPV) affects the skin and moist membranes that line the body. It is a group of more than 100 viruses, and different types of HPV occur in different areas of the body. HPV types 6 and 11 cause more than 90% Trusted Source of genital warts in both sexes. HPV types 16 and 18 cause most HPV-related cancers. Although most males who have HPV do not show any symptoms, some develop growths or warts . These may occur on the: penis testicles anus groin and thighs tongue and top of the mouth Genital warts can be small or large, flat or raised, or cauliflower-shaped. They might appear as a bump or group of bumps in th

More Evidence That ARSIs for Prostate Cancer Differ in Cognitive Effects | MedPage Today — More fatigue, depression, worse reaction time with enzalutamide as compared with abiraterone medpagetoday.com Meeting Coverage > GuCS by Charles Bankhead , Senior Editor, MedPage Today January 29, 2024 SAN FRANCISCO -- Two widely used androgen receptor signaling inhibitors (ARSIs) had a similar overall effect on cognitive function in men with metastatic castration-resistant prostate cancer (mCRPC) but differed significantly for specific components of cognition and mood, a prospective observational study showed. Patients had more fatigue, depression, a

Could two drugs be better than one for treating prostate cancer? | ScienceDaily sciencedaily.com Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, Phase 3 clinical trial led by UC San Francisco researchers has found. The approach can extend the time between debilitating drug treatments without prolonging the time it takes to recover from each treatment. Prostate cancer affects 1 in 8 men and causes 34,000 deaths each year in the United States. It is usually treated with one of several testosterone-lowering drugs for a set period of time. "This adds to a growing body of evidence in favor of more intensive testosterone-blocking therapy in patients with higher-risk prostate cancer," said Rahul Aggarwal, MD, professor in the UCSF School of Medicine and lead author of the paper. T

Fig. 1 . Clinical implications of using the Stockholm-3 model (S3M) as a reflex test for 1000 men aged 50–69 yr with prostate-specific antigen (PSA) in the range 3–10 ng/ml. GS = Gleason score. Another Prostate Cancer Screening Candidate Outperforms Standard PSA Testing | MedPage Today — Multiparametric Stockholm3 avoided far more unnecessary biopsies without sacrificing sensitivity medpagetoday.com Charles Bankhead Meeting Coverage > GuCS by Senior Editor, MedPage Today January 28, 2024 SAN FRANCISCO -- A multiparametric blood test for prostate cancer showed potential to avoid more than half of unnecessary biopsies without sacrificing accuracy, a large

Conference Convenes Experts in the Field of Nuclear Medicine to Advance Prostate Cancer Care | UCSF Radiology radiology.ucsf.edu Announcement January 25, 2024 2024 PSMA Conference group photo “Great science, great technology, great thinking, and great connectivity can change the world,” said Charles J. Ryan, MD, CEO of the Prostate Cancer Foundation, as he welcomed the world’s leading experts in prostate cancer care to the inaugural PSMA Conference , held at University of California, San Francisco, January 18-19, 2024. More than 500 attendees in-person and online explored the current and future use of PSMA (prostate-specific membrane antigen) PET imaging and PSMA radioligand therapy to  improve the clinical care of patients with prostate cancer, the most common cancer among men in the United

Treatment can do more harm than good for prostate cancer − why active surveillance may be a better option for some theconversation.com Jinping Xu Although about 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime, only about 1 in 44 will die from it. Most men diagnosed with prostate cancer die from other causes, especially those with a low-risk prostate cancer that usually grows so slowly it isn’t life-threatening. However, until about a decade ago , most men diagnosed with low-risk prostate cancer were immediately treated with surgery or radiation. Although both can cure the cancer, they can also have serious, life-changing complications, including urinary incontinence and erectile dysfunction. I am a family physician and researcher studying how patient-physician relationships and decision-making processes affect

Study Supports High-Dose RT, Long-Term ADT as Standard for High-Risk Prostate Cancer | MedPage Today medpagetoday.com Charles Bankhead Meeting Coverage > GuCS — OS, PFS, cancer-specific survival all improved, with no increase in toxicity by Charles Bankhead , Senior Editor, MedPage Today January 26, 2024 SAN FRANCISCO -- Men with high-risk localized prostate cancer lived significantly longer with dose-escalated radiation therapy (RT) plus long-term androgen deprivation therapy (ADT), according to long-term follow-up from a randomized trial. After a median follow-up of 9.5 years, the 10-year overall survival (OS) rate inc

Cabozantinib Plus Atezolizumab Delays Progression in mCRPC | MedPage Today medpagetoday.com Mike Bassett Meeting Coverage > GuCS — Combination improved PFS versus more hormonal therapy, but control arm questioned by Mike Bassett , Staff Writer, MedPage Today January 26, 2024 SAN FRANCISCO -- In patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed on a novel hormonal therapy, the combination of cabozantinib (Cabometyx) plus atezolizumab (Tecentriq) improved radiographic progression-free survival (rPFS) versus a switch to a second hormonal agent, a phase III trial showed. The so-